Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for microalbuminuria in T2DM and CHD
NCT03105219Phase 3Withdrawn
- Sponsor
- Nanjing First Hospital
- Start
- Jul 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivabradine in diabetic kidney disease (DKD), sponsored by Nanjing First Hospital. Planned start Jul 2017; status: withdrawn.
02
Drugs
ivabradine
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT03105219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105219.